Immunomedics Inc (IMMU) Return on Equity ROE from the second quarter 2020 to second quarter 2019 and annually, average high and low, overall ranking from Jun 30 2020 to Jun 30 2019 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Immunomedics Inc   (NASDAQ: IMMU)

Immunomedics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Immunomedics Inc in the second quarter 2020?
Immunomedics Inc recorded a cumulative net loss of $-354 million during 12 months ending in the second quarter 2020, resulting in a negative return on equity (ROE) of -132.45%.

Within the In Vitro & In Vivo Diagnostic Substances industry 14 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2020 from 0 to 3816.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2020)
II. Quarter		 (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter		 (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter
Y / Y Equity Change 416.96 % 1.71 % 0.52 % -93.12 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -354 -363 -357 -429 -399
Return On Equity (TTM) -132.45 % -246.07 % -243.51 % -293.23 % -177.1 %
IMMU's Total Ranking # 3816 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 592 185 267 23 115
Seq. Equity Change 220.28 % -30.8 % 1044.16 % -79.61 % -36.99 %
Seq. Net Income Change - - - - -

Back to IMMU Management Effectiveness >> IMMU's 5 Years Annual ROE >> Compare IMMU ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 15
Sector # 609
Overall # 3816

Return On Equity Statistics
High Average Low
-27.37 %
-178.15 %
-447.64 %
(Sep 30 2013)   (Jun 30 2015)





IMMU Annual Return On Equity (Dec 31 2019)
2019		 (Jun 30 2018)
2018		 (Jun 30 2017)
2017		 (Jun 30 2016)
2016		 (Jun 30 2015)
2015
Total Equity in Millions 267 400 -59 -58 -5
Y / Y Equity Change -33.14 % - - - -
Net Income in Millions -357 -274 -153 -59 -48
Y / Y Net Income Change - - - - -
Return On Equity -133.71 % -68.53 % - - -

Back to IMMU Management Effectiveness >> IMMU's 5 Years Annual ROE >> Compare IMMU ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IMMU's' Return on Equity at Yahoo Finance
IMMU's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IMMU's Competitors
Subscribers only: Roe for Immunomedics Inc 's Suppliers
Subscribers only: Return On Equity for IMMU's Customers




Companies with similar Return On Equity at Jun 30 2020, within Healthcare Sector ROE

Date modified: 2026-09-08T15:10:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.